Increased AURKA Gene Copy Number Correlates with Poor Prognosis and Predicts the Efficacy of High-dose Interferon Therapy in Acral Melanoma

Conclusions: This study suggested that AURKA copy gain is an adverse prognostic factor for AM. Furthermore, AURKA copy gain may be a useful biomarker to predict the outcome of interferon therapy in patients with AM.

Source: Journal of Cancer - June 20, 2018 Category: Cancer & Oncology Authors: Junya Yan, Jiayi Yu, Xiaowen Wu, Tianxiao Xu, Huan Yu, Jie Dai, Meng Ma, Huan Tang, Longwen Xu, Zhihong Chi, Lu Si, Xinan Sheng, Chuanliang Cui, Yan Kong, Jun Guo Tags: Research Paper Source Type: research